Business Context and Reporting Period
This Form 8-K Current Report was filed by Bruker Corporation on May 20, 2016. The filing primarily addresses corporate governance and management matters, specifically the formalization of executive compensation plans following stockholder approval at the 2016 Annual Meeting of Stockholders.
Key Financial Metrics
This filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. The only financial data provided relates to the 2016 compensation targets for Named Executive Officers (NEOs):
| Executive Officer | Title | 2016 Base Salary | 2016 Short-Term Incentive Target | Target as % of Base |
|---|---|---|---|---|
| Frank H. Laukien, Ph.D. | President and CEO | $680,000 | $952,000 | 140% |
| Anthony L. Mattacchione | CFO and SVP | $418,000 | $271,700 | 65% |
| Mark R. Munch, Ph.D. | EVP, Bruker Nano Group | $504,700 | $302,800 | 60% |
| Juergen Srega | President, Bruker CALID Group | $355,137 | $195,370 | 55% |
| Rene Lenggenhager, Ph.D. | President, Bruker BioSpin Group | $379,768 | $133,432 | 35% |
| Michael Knell | VP of Finance and CAO | $233,200 | $93,300 | 40% |
Note: Figures for Mr. Srega and Dr. Lenggenhager are converted from EUR and CHF, respectively, using rates as of March 23, 2016.
Material Changes
The filing reports that the 2016 Short-Term Incentive Compensation Program (2016 Short-Term ICP) and individual cash incentive plans for executive officers, which were previously approved on a contingent basis by the Compensation Committee in March 2016, have become effective. This effectiveness was contingent upon stockholder approval of the Bruker Corporation 2016 Incentive Compensation Plan (2016 Plan), which was granted at the 2016 Annual Meeting.
Guidance, Outlook, and Management Commentary
The filing outlines the performance metrics driving executive compensation for 2016:
- Structure: 70% of the cash incentive award potential is based on quantitative financial factors, while 30% is based on individual qualitative factors.
- Corporate Goals: For the CEO, CFO, and CAO, quantitative goals include currency-adjusted revenue growth, non-GAAP operating profit improvement, non-GAAP earnings per share growth, and reduction in the working capital ratio.
- Segment Goals: For division presidents (Nano, CALID, BioSpin), approximately 85% of quantitative goals are tied to their specific segment's performance (revenue growth, gross profit improvement, operating profit improvement, working capital ratio), with 15% tied to corporate operating profit.
- Payout Limits:
- Qualitative goals range from 0% to 125% of target.
- Quantitative goals generally have no threshold or maximum.
- Total short-term incentive awards are capped at 200% of the target level.
- Dr. Munch has a specific floor of 50% on the segment-specific quantitative portion (approx. 30% of total target).
Investor Verification Checklist
- Verify the final payout amounts for 2016 executive bonuses against the reported performance goals (revenue growth, operating profit, EPS, working capital) in the subsequent annual report.
- Confirm the actual currency exchange rates used for final compensation calculations for international executives (Mr. Srega and Dr. Lenggenhager) versus the March 2016 rates cited in this filing.
- Review the attached Exhibit 10.1 (2016 Short-Term Incentive Compensation Program) for detailed definitions of "non-GAAP" metrics and specific performance thresholds.
- Monitor future filings for any changes to the 200% maximum payout cap or the 70/30 quantitative/qualitative split.